5:34 PM
 | 
Mar 26, 2013
 |  BC Extra  |  Top Story

Ziopharm plummets on palifosfamide miss

Ziopharm Oncology Inc. (NASDAQ:ZIOP) fell $3.31 (65%) to $1.82 on Tuesday after the company discontinued development of Zymafos palifosfamide as first-line treatment of soft tissue sarcoma (STS). The move came after IV Zymafos plus doxorubicin missed the primary endpoint of improving progression-free survival (PFS) vs. doxorubicin alone in the Phase III PICASSO 3 trial in 447 anthracycline-naïve patients with...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >